aluates Reports

$ 0.0

Automative

Global Hyperphosphatemia Treatment Market Research Report 2025

Published Date: January 2025

Report Code: QYRE-Auto-36G13357

Global Hyperphosphatemia Treatment Market Research Report 2023

BUY CHAPTERS

Global Hyperphosphatemia Treatment Market Research Report 2025

Code: QYRE-Auto-36G13357

Report

January 2025

Pages:81

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sanofi

Takeda Pharmaceutical Company Limited

Astellas Pharma Inc

Akebia Therapeutics, Inc.

Vifor Pharma Management, Ltd.

Lupin Ltd

Ardelyx Inc

Keryx Biopharmaceuticals

Unicycive Therapeutics Inc.

Zeria Pharmaceutical

Fresenius Medical

Rockwell Medical

Hyperphosphatemia Treatment Market Size

The global market for Hyperphosphatemia Treatment was valued at US$ 2680 million in the year 2024 and is projected to reach a revised size of US$ 3853 million by 2031, growing at a CAGR of 5.4% during the forecast period.

Hyperphosphatemia Treatment Market

Hyperphosphatemia is a serum phosphate concentration > 4.5 mg/dL (> 1.46 mmol/L). Causes include chronic kidney disease, hypoparathyroidism, and metabolic or respiratory acidosis. Clinical features may be due to accompanying hypocalcemia and include tetany. Diagnosis is by serum phosphate measurement. Treatment includes restriction of phosphate intake and administration of phosphate-binding antacids, such as calcium carbonate.

The global hyperphosphatemia treatment market refers to the market for medications and therapies used in the management of hyperphosphatemia. Hyperphosphatemia is a condition characterized by abnormally high levels of phosphate in the blood. Elevated phosphate levels can have serious implications for individuals with chronic kidney disease, kidney failure, or other medical conditions.

The market for hyperphosphatemia treatment is driven by several factors:

Increasing prevalence of chronic kidney disease: Chronic kidney disease (CKD) is a significant contributor to hyperphosphatemia. As the global prevalence of CKD continues to rise, so does the demand for effective treatments for hyperphosphatemia. According to the National Kidney Foundation, an estimated 10% of the global population is affected by CKD.

Growing awareness and diagnosis: There is an increasing awareness of the impact of hyperphosphatemia on overall health and its association with complications such as cardiovascular diseases and bone disorders. This has led to more proactive diagnosis and treatment of hyperphosphatemia, driving market growth.

Advancements in treatment options: The market for hyperphosphatemia treatment has witnessed advancements in treatment options, including phosphate binders, which help reduce the absorption of phosphate from the diet. Manufacturers are developing novel phosphate binders with improved efficacy and tolerability, driving market growth.

Collaborative efforts to improve patient care: Healthcare organizations, research institutions, and pharmaceutical companies are actively collaborating to develop innovative solutions for hyperphosphatemia management. These collaborations aim to enhance patient care outcomes and drive market expansion.

Government initiatives and reimbursement policies: Governments in several countries have implemented initiatives and reimbursement policies to improve access to hyperphosphatemia treatments. This has positively influenced market growth by making these therapies more affordable and accessible to patients.

The global hyperphosphatemia treatment market includes various treatment options such as phosphate binders, dietary restrictions, dialysis, and medications that lower phosphate levels. Some of the key players in this market include Vifor Pharma, Keryx Biopharmaceuticals, Sanofi, Fresenius Medical Care AG & Co. KGaA, and Rockwell Medical, among others.

In conclusion, the global hyperphosphatemia treatment market is driven by the increasing prevalence of chronic kidney disease, growing awareness and diagnosis of hyperphosphatemia, advancements in treatment options, collaborative efforts to improve patient care, and favorable government initiatives. As the importance of managing hyperphosphatemia becomes more evident, the demand for effective treatment options is expected to increase, driving market growth in the coming years.

This report aims to provide a comprehensive presentation of the global market for Hyperphosphatemia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hyperphosphatemia Treatment.

The Hyperphosphatemia Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hyperphosphatemia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hyperphosphatemia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Hyperphosphatemia Treatment Market Report

Report Metric	Details
Report Name	Hyperphosphatemia Treatment Market
Accounted market size in year	US$ 2680 million
Forecasted market size in 2031	US$ 3853 million
CAGR	5.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Sevelamer Calcium-based Phosphate Binders Iron-based Phosphate Binders Lanthanum Carbonate Non-phosphate Binders Others
Segment by Application	Hospital Pharmacy Retail Pharmacy Online Stores Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics,Inc, Vifor Pharma Management Ltd., Lupin Limited, Ardelyx,Inc., Unicycive Therapeutics Inc., Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fresenius Medical, Rockwell Medical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hyperphosphatemia Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Hyperphosphatemia Treatment Market growing?

Ans: The Hyperphosphatemia Treatment Market witnessing a CAGR of 5.4% during the forecast period 2025-2031.

What is the Hyperphosphatemia Treatment Market size in 2031?

Ans: The Hyperphosphatemia Treatment Market size in 2031 will be US$ 3853 million.

Who are the main players in the Hyperphosphatemia Treatment Market report?

Ans: The main players in the Hyperphosphatemia Treatment Market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics,Inc, Vifor Pharma Management Ltd., Lupin Limited, Ardelyx,Inc., Unicycive Therapeutics Inc., Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fresenius Medical, Rockwell Medical

What are the Application segmentation covered in the Hyperphosphatemia Treatment Market report?

Ans: The Applications covered in the Hyperphosphatemia Treatment Market report are Hospital Pharmacy, Retail Pharmacy, Online Stores, Others

What are the Type segmentation covered in the Hyperphosphatemia Treatment Market report?

Ans: The Types covered in the Hyperphosphatemia Treatment Market report are Sevelamer, Calcium-based Phosphate Binders, Iron-based Phosphate Binders, Lanthanum Carbonate, Non-phosphate Binders, Others

Recommended Reports

Kidney Disease Therapy

Phosphate Compound Markets

Vitamin & Metabolic Disorders

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Hyperphosphatemia Treatment Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Sevelamer

1.2.3 Calcium-based Phosphate Binders

1.2.4 Iron-based Phosphate Binders

1.2.5 Lanthanum Carbonate

1.2.6 Non-phosphate Binders

1.2.7 Others

1.3 Market by Application

1.3.1 Global Hyperphosphatemia Treatment Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Online Stores

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Hyperphosphatemia Treatment Market Perspective (2020-2031)

2.2 Global Hyperphosphatemia Treatment Growth Trends by Region

2.2.1 Global Hyperphosphatemia Treatment Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Hyperphosphatemia Treatment Historic Market Size by Region (2020-2025)

2.2.3 Hyperphosphatemia Treatment Forecasted Market Size by Region (2026-2031)

2.3 Hyperphosphatemia Treatment Market Dynamics

2.3.1 Hyperphosphatemia Treatment Industry Trends

2.3.2 Hyperphosphatemia Treatment Market Drivers

2.3.3 Hyperphosphatemia Treatment Market Challenges

2.3.4 Hyperphosphatemia Treatment Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Hyperphosphatemia Treatment Players by Revenue

3.1.1 Global Top Hyperphosphatemia Treatment Players by Revenue (2020-2025)

3.1.2 Global Hyperphosphatemia Treatment Revenue Market Share by Players (2020-2025)

3.2 Global Hyperphosphatemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Hyperphosphatemia Treatment Revenue

3.4 Global Hyperphosphatemia Treatment Market Concentration Ratio

3.4.1 Global Hyperphosphatemia Treatment Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Hyperphosphatemia Treatment Revenue in 2024

3.5 Global Key Players of Hyperphosphatemia Treatment Head office and Area Served

3.6 Global Key Players of Hyperphosphatemia Treatment, Product and Application

3.7 Global Key Players of Hyperphosphatemia Treatment, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Hyperphosphatemia Treatment Breakdown Data by Type

4.1 Global Hyperphosphatemia Treatment Historic Market Size by Type (2020-2025)

4.2 Global Hyperphosphatemia Treatment Forecasted Market Size by Type (2026-2031)

5 Hyperphosphatemia Treatment Breakdown Data by Application

5.1 Global Hyperphosphatemia Treatment Historic Market Size by Application (2020-2025)

5.2 Global Hyperphosphatemia Treatment Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Hyperphosphatemia Treatment Market Size (2020-2031)

6.2 North America Hyperphosphatemia Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Hyperphosphatemia Treatment Market Size by Country (2020-2025)

6.4 North America Hyperphosphatemia Treatment Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Hyperphosphatemia Treatment Market Size (2020-2031)

7.2 Europe Hyperphosphatemia Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Hyperphosphatemia Treatment Market Size by Country (2020-2025)

7.4 Europe Hyperphosphatemia Treatment Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Hyperphosphatemia Treatment Market Size (2020-2031)

8.2 Asia-Pacific Hyperphosphatemia Treatment Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Hyperphosphatemia Treatment Market Size by Region (2020-2025)

8.4 Asia-Pacific Hyperphosphatemia Treatment Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Hyperphosphatemia Treatment Market Size (2020-2031)

9.2 Latin America Hyperphosphatemia Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Hyperphosphatemia Treatment Market Size by Country (2020-2025)

9.4 Latin America Hyperphosphatemia Treatment Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Hyperphosphatemia Treatment Market Size (2020-2031)

10.2 Middle East & Africa Hyperphosphatemia Treatment Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Hyperphosphatemia Treatment Market Size by Country (2020-2025)

10.4 Middle East & Africa Hyperphosphatemia Treatment Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sanofi

11.1.1 Sanofi Company Details

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Hyperphosphatemia Treatment Introduction

11.1.4 Sanofi Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.1.5 Sanofi Recent Development

11.2 Takeda Pharmaceutical Company Limited

11.2.1 Takeda Pharmaceutical Company Limited Company Details

11.2.2 Takeda Pharmaceutical Company Limited Business Overview

11.2.3 Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Introduction

11.2.4 Takeda Pharmaceutical Company Limited Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.2.5 Takeda Pharmaceutical Company Limited Recent Development

11.3 Astellas Pharma Inc.

11.3.1 Astellas Pharma Inc. Company Details

11.3.2 Astellas Pharma Inc. Business Overview

11.3.3 Astellas Pharma Inc. Hyperphosphatemia Treatment Introduction

11.3.4 Astellas Pharma Inc. Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.3.5 Astellas Pharma Inc. Recent Development

11.4 Akebia Therapeutics,Inc

11.4.1 Akebia Therapeutics,Inc Company Details

11.4.2 Akebia Therapeutics,Inc Business Overview

11.4.3 Akebia Therapeutics,Inc Hyperphosphatemia Treatment Introduction

11.4.4 Akebia Therapeutics,Inc Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.4.5 Akebia Therapeutics,Inc Recent Development

11.5 Vifor Pharma Management Ltd.

11.5.1 Vifor Pharma Management Ltd. Company Details

11.5.2 Vifor Pharma Management Ltd. Business Overview

11.5.3 Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Introduction

11.5.4 Vifor Pharma Management Ltd. Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.5.5 Vifor Pharma Management Ltd. Recent Development

11.6 Lupin Limited

11.6.1 Lupin Limited Company Details

11.6.2 Lupin Limited Business Overview

11.6.3 Lupin Limited Hyperphosphatemia Treatment Introduction

11.6.4 Lupin Limited Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.6.5 Lupin Limited Recent Development

11.7 Ardelyx,Inc.

11.7.1 Ardelyx,Inc. Company Details

11.7.2 Ardelyx,Inc. Business Overview

11.7.3 Ardelyx,Inc. Hyperphosphatemia Treatment Introduction

11.7.4 Ardelyx,Inc. Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.7.5 Ardelyx,Inc. Recent Development

11.8 Unicycive Therapeutics Inc.

11.8.1 Unicycive Therapeutics Inc. Company Details

11.8.2 Unicycive Therapeutics Inc. Business Overview

11.8.3 Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Introduction

11.8.4 Unicycive Therapeutics Inc. Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.8.5 Unicycive Therapeutics Inc. Recent Development

11.9 Keryx Biopharmaceuticals

11.9.1 Keryx Biopharmaceuticals Company Details

11.9.2 Keryx Biopharmaceuticals Business Overview

11.9.3 Keryx Biopharmaceuticals Hyperphosphatemia Treatment Introduction

11.9.4 Keryx Biopharmaceuticals Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.9.5 Keryx Biopharmaceuticals Recent Development

11.10 Zeria Pharmaceutical

11.10.1 Zeria Pharmaceutical Company Details

11.10.2 Zeria Pharmaceutical Business Overview

11.10.3 Zeria Pharmaceutical Hyperphosphatemia Treatment Introduction

11.10.4 Zeria Pharmaceutical Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.10.5 Zeria Pharmaceutical Recent Development

11.11 Fresenius Medical

11.11.1 Fresenius Medical Company Details

11.11.2 Fresenius Medical Business Overview

11.11.3 Fresenius Medical Hyperphosphatemia Treatment Introduction

11.11.4 Fresenius Medical Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.11.5 Fresenius Medical Recent Development

11.12 Rockwell Medical

11.12.1 Rockwell Medical Company Details

11.12.2 Rockwell Medical Business Overview

11.12.3 Rockwell Medical Hyperphosphatemia Treatment Introduction

11.12.4 Rockwell Medical Revenue in Hyperphosphatemia Treatment Business (2020-2025)

11.12.5 Rockwell Medical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Sanofi

Takeda Pharmaceutical Company Limited

Astellas Pharma Inc

Akebia Therapeutics, Inc.

Vifor Pharma Management, Ltd.

Lupin Ltd

Ardelyx Inc

Keryx Biopharmaceuticals

Unicycive Therapeutics Inc.

Zeria Pharmaceutical

Fresenius Medical

Rockwell Medical

List of Tables

Table 1. Global Hyperphosphatemia Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Sevelamer

Table 3. Key Players of Calcium-based Phosphate Binders

Table 4. Key Players of Iron-based Phosphate Binders

Table 5. Key Players of Lanthanum Carbonate

Table 6. Key Players of Non-phosphate Binders

Table 7. Key Players of Others

Table 8. Global Hyperphosphatemia Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 9. Global Hyperphosphatemia Treatment Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 10. Global Hyperphosphatemia Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 11. Global Hyperphosphatemia Treatment Market Share by Region (2020-2025)

Table 12. Global Hyperphosphatemia Treatment Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 13. Global Hyperphosphatemia Treatment Market Share by Region (2026-2031)

Table 14. Hyperphosphatemia Treatment Market Trends

Table 15. Hyperphosphatemia Treatment Market Drivers

Table 16. Hyperphosphatemia Treatment Market Challenges

Table 17. Hyperphosphatemia Treatment Market Restraints

Table 18. Global Hyperphosphatemia Treatment Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global Hyperphosphatemia Treatment Market Share by Players (2020-2025)

Table 20. Global Top Hyperphosphatemia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperphosphatemia Treatment as of 2024)

Table 21. Ranking of Global Top Hyperphosphatemia Treatment Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by Hyperphosphatemia Treatment Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of Hyperphosphatemia Treatment, Headquarters and Area Served

Table 24. Global Key Players of Hyperphosphatemia Treatment, Product and Application

Table 25. Global Key Players of Hyperphosphatemia Treatment, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Hyperphosphatemia Treatment Market Size by Type (2020-2025) & (US$ Million)

Table 28. Global Hyperphosphatemia Treatment Revenue Market Share by Type (2020-2025)

Table 29. Global Hyperphosphatemia Treatment Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 30. Global Hyperphosphatemia Treatment Revenue Market Share by Type (2026-2031)

Table 31. Global Hyperphosphatemia Treatment Market Size by Application (2020-2025) & (US$ Million)

Table 32. Global Hyperphosphatemia Treatment Revenue Market Share by Application (2020-2025)

Table 33. Global Hyperphosphatemia Treatment Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 34. Global Hyperphosphatemia Treatment Revenue Market Share by Application (2026-2031)

Table 35. North America Hyperphosphatemia Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. North America Hyperphosphatemia Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 37. North America Hyperphosphatemia Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 38. Europe Hyperphosphatemia Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 39. Europe Hyperphosphatemia Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 40. Europe Hyperphosphatemia Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 41. Asia-Pacific Hyperphosphatemia Treatment Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 42. Asia-Pacific Hyperphosphatemia Treatment Market Size by Region (2020-2025) & (US$ Million)

Table 43. Asia-Pacific Hyperphosphatemia Treatment Market Size by Region (2026-2031) & (US$ Million)

Table 44. Latin America Hyperphosphatemia Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Latin America Hyperphosphatemia Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 46. Latin America Hyperphosphatemia Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 47. Middle East & Africa Hyperphosphatemia Treatment Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 48. Middle East & Africa Hyperphosphatemia Treatment Market Size by Country (2020-2025) & (US$ Million)

Table 49. Middle East & Africa Hyperphosphatemia Treatment Market Size by Country (2026-2031) & (US$ Million)

Table 50. Sanofi Company Details

Table 51. Sanofi Business Overview

Table 52. Sanofi Hyperphosphatemia Treatment Product

Table 53. Sanofi Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 54. Sanofi Recent Development

Table 55. Takeda Pharmaceutical Company Limited Company Details

Table 56. Takeda Pharmaceutical Company Limited Business Overview

Table 57. Takeda Pharmaceutical Company Limited Hyperphosphatemia Treatment Product

Table 58. Takeda Pharmaceutical Company Limited Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 59. Takeda Pharmaceutical Company Limited Recent Development

Table 60. Astellas Pharma Inc. Company Details

Table 61. Astellas Pharma Inc. Business Overview

Table 62. Astellas Pharma Inc. Hyperphosphatemia Treatment Product

Table 63. Astellas Pharma Inc. Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 64. Astellas Pharma Inc. Recent Development

Table 65. Akebia Therapeutics,Inc Company Details

Table 66. Akebia Therapeutics,Inc Business Overview

Table 67. Akebia Therapeutics,Inc Hyperphosphatemia Treatment Product

Table 68. Akebia Therapeutics,Inc Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 69. Akebia Therapeutics,Inc Recent Development

Table 70. Vifor Pharma Management Ltd. Company Details

Table 71. Vifor Pharma Management Ltd. Business Overview

Table 72. Vifor Pharma Management Ltd. Hyperphosphatemia Treatment Product

Table 73. Vifor Pharma Management Ltd. Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 74. Vifor Pharma Management Ltd. Recent Development

Table 75. Lupin Limited Company Details

Table 76. Lupin Limited Business Overview

Table 77. Lupin Limited Hyperphosphatemia Treatment Product

Table 78. Lupin Limited Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 79. Lupin Limited Recent Development

Table 80. Ardelyx,Inc. Company Details

Table 81. Ardelyx,Inc. Business Overview

Table 82. Ardelyx,Inc. Hyperphosphatemia Treatment Product

Table 83. Ardelyx,Inc. Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 84. Ardelyx,Inc. Recent Development

Table 85. Unicycive Therapeutics Inc. Company Details

Table 86. Unicycive Therapeutics Inc. Business Overview

Table 87. Unicycive Therapeutics Inc. Hyperphosphatemia Treatment Product

Table 88. Unicycive Therapeutics Inc. Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 89. Unicycive Therapeutics Inc. Recent Development

Table 90. Keryx Biopharmaceuticals Company Details

Table 91. Keryx Biopharmaceuticals Business Overview

Table 92. Keryx Biopharmaceuticals Hyperphosphatemia Treatment Product

Table 93. Keryx Biopharmaceuticals Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 94. Keryx Biopharmaceuticals Recent Development

Table 95. Zeria Pharmaceutical Company Details

Table 96. Zeria Pharmaceutical Business Overview

Table 97. Zeria Pharmaceutical Hyperphosphatemia Treatment Product

Table 98. Zeria Pharmaceutical Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 99. Zeria Pharmaceutical Recent Development

Table 100. Fresenius Medical Company Details

Table 101. Fresenius Medical Business Overview

Table 102. Fresenius Medical Hyperphosphatemia Treatment Product

Table 103. Fresenius Medical Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 104. Fresenius Medical Recent Development

Table 105. Rockwell Medical Company Details

Table 106. Rockwell Medical Business Overview

Table 107. Rockwell Medical Hyperphosphatemia Treatment Product

Table 108. Rockwell Medical Revenue in Hyperphosphatemia Treatment Business (2020-2025) & (US$ Million)

Table 109. Rockwell Medical Recent Development

Table 110. Research Programs/Design for This Report

Table 111. Key Data Information from Secondary Sources

Table 112. Key Data Information from Primary Sources

Table 113. Authors List of This Report

List of Figures

Figure 1. Hyperphosphatemia Treatment Picture

Figure 2. Global Hyperphosphatemia Treatment Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hyperphosphatemia Treatment Market Share by Type: 2024 VS 2031

Figure 4. Sevelamer Features

Figure 5. Calcium-based Phosphate Binders Features

Figure 6. Iron-based Phosphate Binders Features

Figure 7. Lanthanum Carbonate Features

Figure 8. Non-phosphate Binders Features

Figure 9. Others Features

Figure 10. Global Hyperphosphatemia Treatment Market Size by Application (2020-2031) & (US$ Million)

Figure 11. Global Hyperphosphatemia Treatment Market Share by Application: 2024 VS 2031

Figure 12. Hospital Pharmacy Case Studies

Figure 13. Retail Pharmacy Case Studies

Figure 14. Online Stores Case Studies

Figure 15. Others Case Studies

Figure 16. Hyperphosphatemia Treatment Report Years Considered

Figure 17. Global Hyperphosphatemia Treatment Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 18. Global Hyperphosphatemia Treatment Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 19. Global Hyperphosphatemia Treatment Market Share by Region: 2024 VS 2031

Figure 20. Global Hyperphosphatemia Treatment Market Share by Players in 2024

Figure 21. Global Top Hyperphosphatemia Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hyperphosphatemia Treatment as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by Hyperphosphatemia Treatment Revenue in 2024

Figure 23. North America Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. North America Hyperphosphatemia Treatment Market Share by Country (2020-2031)

Figure 25. United States Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. Canada Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Europe Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Europe Hyperphosphatemia Treatment Market Share by Country (2020-2031)

Figure 29. Germany Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. France Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. U.K. Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Italy Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Russia Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Nordic Countries Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Asia-Pacific Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Hyperphosphatemia Treatment Market Share by Region (2020-2031)

Figure 37. China Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Japan Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. South Korea Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Southeast Asia Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. India Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Australia Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Latin America Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Latin America Hyperphosphatemia Treatment Market Share by Country (2020-2031)

Figure 45. Mexico Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. Brazil Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Middle East & Africa Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Middle East & Africa Hyperphosphatemia Treatment Market Share by Country (2020-2031)

Figure 49. Turkey Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Saudi Arabia Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. UAE Hyperphosphatemia Treatment Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Sanofi Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 53. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 54. Astellas Pharma Inc. Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 55. Akebia Therapeutics,Inc Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 56. Vifor Pharma Management Ltd. Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 57. Lupin Limited Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 58. Ardelyx,Inc. Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 59. Unicycive Therapeutics Inc. Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 60. Keryx Biopharmaceuticals Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 61. Zeria Pharmaceutical Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 62. Fresenius Medical Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 63. Rockwell Medical Revenue Growth Rate in Hyperphosphatemia Treatment Business (2020-2025)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Hyperkalemia Treatment Market Research Report 2025

Global Phosphate Binders Market Insights Forecast to 2030

Hyperkalaemia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Food Grade Dicalcium Phosphate Dihydrate Market Research Report 2024

Global Pharmaceutical Grade Dicalcium Phosphate Dihydrate Market Research Report 2025

Global Primary Hyperoxaluria Treatment Market Research Report 2025

Global Calcium Acetate Tablet Market Research Report 2024

Vitamin Deficiency Treatment Market

Global Food Grade Pharma Grade Calcium Phosphate Market Research Report 2025

Global Fertilizer Grade Phosphate Market Research Report 2024

Global Pharmaceutical Grade Anhydrous Calcium Hydrogen Phosphate Market Research Report 2025

Global Feed Grade Phosphate Market Research Report 2024

Global Food Grade Calcium Dihydrogen Phosphate Market Research Report 2024

Global Phosphate Binding Agent Market Research Report 2024

Global Crysvita Injection Market Research Report 2025

Global Food Grade Phosphate Market Research Report 2024

Global Feed Grade Dicalcium Phosphate Market Insights Forecast to 2030

Global Tetracalcium Phosphate Market Research Report 2024

Global Monodicalcium Phosphate Market Research Report 2024

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Chronic Pain Medical Devices Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-0I20198

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Disposable Insulin Pen Needle Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-33W11115

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Low-Density Lipoprotein Cholesterol Assay Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-32E19705

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions